IRCT20200328046885N1 IRCT 2020-10-12 Iran University of Medical Sciences Comparison of the effectiveness of two treatment regimens in patients with COVID-19 Comparison of the effectiveness of Sovodak (sofosbuvir + Daklatasvir) and Keltra treatment regimens in patients with COVID-19: a randomized single-blind study 2020-07-19 anticipated 300 Complete https://irct.ir/trial/47565 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: How patients are randomized will be classified as randomization blocks. Patients who need hospitalization are divided into four categories based on SpO2 and high-risk groups at the beginning of the visit, including patients in the high-risk group with SaO2 below 93%, patients in the high-risk group with high or equal SaO2 93%, patients in the group Low risk with SaO2 below 93% and finally patients in the low risk group with high SaO2 or equal to 93% will be divided. High-risk criteria include age over 60, with underlying disease such as immunodeficiency, diabetes, cardiovascular disease, obstructive pulmonary disease, malignancies, immunosuppressive patients, patients undergoing chemotherapy, chronic liver disease including cirrhosis and chronic disease Kidney will be considered. In each floor, blocks of size 4 are considered so that assuming the drug combination of chloroquine + Sovodak (sofosbuvir + Daklatasvir) as drug combination A and drug combination chloroquine + Kaletra as B, permutations of blocks in the form of AABB, ABAB, BBAA , BABA, ABBA, and BAAB will be produced. The sequence of blocks is randomly determined and patients in all four classes are named, thus depending on the time of referral will be placed in these blocks in order. It should be noted that the preparation of blocks and the placement of patients in blocks (assignment of patients to treatment groups) will be done by a third party who is not directly involved in the treatment of patients. Medications will also be prescribed by the clinical staff (assistants of the relevant departments) who are not involved in conducting this study, Blinding description: Medications will also be prescribed by the clinical staff (assistants of the relevant departments) who are not involved in conducting this study. And trying to be a double-blind experiment. Treatment regimen in group A. Hydroxychloroquine phosphate 400 mg single dose + lupinavir / ritonavir 400/100 combination twice daily for at least 5 days Treatment regimen in group B. Hydroxychloroquine phosphate 400 mg every 12 hours for the first day and then 200 mg every 12 hours for 5 to 7 days + Sovodak (sofosbuvir + Daklatasvir) once a day (60/400 mg) for at least 5 to 7 days It should be noted that each treatment regimen for each patient will be placed in separate envelopes with labels known only to the prescriber (a third party who will be selected by a medical staff that is not directly involved in the study). In order to blind the contents of the tablets Sovodak (sofosbuvir + Daklatasvir) and Kaletra, in coordination with a hospital pharmacologist, will be placed inside the same capsules whose contents have been emptied. 3 Covid-19. Intervention 1: Intervention group: out of 300 patients, 150 patients with coronary artery from two medical centers (Rasoul Akram Hospital and Firoozgar Hospital) hydroxychloroquine phosphate treatment regimen 400 mg every 12 hours on the first day and then 200 mg every 12 hours for 5 to 7 Day + Sovodak (sofosbuvir + Daklatasvir) will be taken once a day (60/400 mg) for at least 5 to 7 days. Sovodak drug manufacturer is Faravan Rojan Mohaghegh Daroo (made in Iran) and chloroquine manufacturing company is Iran Daru (made in Iran). Intervention 2: Intervention group: out of 300 patients, 150 patients with coronary artery from two medical centers (Rasoul Akram Hospital and Firoozgar Hospital) Hydroxychloroquine phosphate treatment regimen 400 mg single dose + lupinavir / ritonavir combination 400/100 twice daily They will receive at least 5 days. The manufacturer of the drug is lupinavir / ritonavir (Kaletra), Gilead (made in Iran) and the manufacturer of chloroquine, Iran Daru (made in Iran). No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no further information.